Leucinosis, or maple syrup urine disease (lecture and a clinical case)

Cover Page


Cite item

Full Text

Abstract

Maple syrup urine disease (leucinosis, short-chain ketoaciduria, branched-chain disease, branched-chain ketonuria) is an autosomal recessive disorder which is a consequence of the deficient branched-chain alpha ketoacid dehydrogenase complex. There are five subtypes of the disease: classical, intermediate, intermittent, thiamine-dependent and E3-deficient. Leucinosis is characterized by high plasma levels of branched-chain amino acids (leucine, isoleucine and valine) and high urine levels of branched-chain ketoacids, as well as of lactate and pyruvate. Tandem mass spectrometry can be used as a screening method in newborns. Mild disease cannot be identified at screening. The diagnosis should be based on tandem mass spectrometry of a blood sample and aminoacid analysis by gas chromatography of a urine sample. Prenatal diagnosis requires molecular genetic tests. Treatment of maple syrup urine disease is aimed at normalization of plasma branched-chain amino acids levels and includes two main components, namely, life-long diet therapy and active treatment of acute metabolic deterioration episodes. A favorable course of the disease is possible only with early (pre-symptomatic) initiation of treatment. The development of cognitive functions depends on plasma leucine levels. We present a clinical case of delayed diagnosis of leucinosis, despite its early clinical manifestation, leading to irreversible consequences for the patient.

About the authors

Ju. A. Tsareva

Saratov State Medical University named after V.I. Razumovsky

Author for correspondence.
Email: jutsareva@gmail.com
ORCID iD: 0000-0002-3483-7170

Julia A. Tsareva – MD, PhD, Associate Professor, Сhair of Pediatrics, Center of Continuing Professional Education

112 Bol'shaya Kazach'ya ul., Saratov, Saratovskaya oblast', 410012

Tel.: +7 (909) 340 85 89

Россия

N. I. Zryachkin

Saratov State Medical University named after V.I. Razumovsky

Email: nizryach@yandex.ru
ORCID iD: 0000-0003-1953-0389

Nikolay I. Zryachkin – MD, PhD, Professor, Head of the Сhair of Pediatrics, Center of Continuing Professional Education

112 Bol'shaya Kazach'ya ul., Saratov, Saratovskaya oblast', 410012

Россия

M. A. Kuznetsova

Saratov State Medical University named after V.I. Razumovsky

Email: kma1961@yandex.ru
ORCID iD: 0000-0003-4372-4132

Marina A. Kuznetsova – MD, PhD, Assistant Professor, Сhair of Pediatrics, Center of Continuing Professional Education

112 Bol'shaya Kazach'ya ul., Saratov, Saratovskaya oblast', 410012

Россия

E. V. Bogacheva

Atkarsk District Hospital

Email: bogachevaev1958@yandex.ru

Ekaterina V. Bogacheva – MD, District Pediatrician of Child Welfare Clinic

23 Vali Makeevoy ul., Atkarsk, Saratovskaya oblast', 412423

Россия

References

  1. Menkes JH, Hurst PL, Craig JM. A new syndrome: progressive familial infantile cerebral dysfunction associated with an unusual urinary substance. Pediatrics. 1954;14(5): 462–7.
  2. Naylor EW. Newborn screening for maple syrup urine disease (branched-chain ketoaciduria). In: Bickel H, Guthrie R, Hammersen G, editors. Neonatal screening for inborn errors of metabolism. Berlin: Springer Verlag; 1980. p. 19–28. doi: 10.1007/978-3-642-67488-4_3.
  3. Chapman KA, Gramer G, Viall S, Summar ML. Incidence of maple syrup urine disease, propionic acidemia, and methylmalonic aciduria from newborn screening data. Mol Genet Metab Rep. 2018;15:106–9. doi: 10.1016/j.ymgmr.2018.03.011.
  4. Quental S, Vilarinho L, Martins E, Teles EL, Rodrigues E, Diogo L, Garcia P, Eusébio F, Gaspar A, Sequeira S, Amorim A, Prata MJ. Incidence of maple syrup urine disease in Portugal. Mol Genet Metab. 2010;100(4):385–7. doi: 10.1016/j.ymgme.2010.04.007.
  5. Puffenberger EG. Genetic heritage of the Old Order Mennonites of southeastern Pennsylvania. Am J Med Genet C Semin Med Genet. 2003;121C(1):18–31. doi: 10.1002/ajmg.c.20003.
  6. Burrage LC, Nagamani SC, Campeau PM, Lee BH. Branched-chain amino acid metabolism: from rare Mendelian diseases to more common disorders. Hum Mol Genet. 2014;23(R1):R1–8. doi: 10.1093/hmg/ddu123.
  7. Brosnan JT, Brosnan ME. Branched-chain amino acids: enzyme and substrate regulation. J Nutr. 2006;136(1 Suppl):207–11S. doi: 10.1093/jn/136.1.207S.
  8. Wang XL, Li CJ, Xing Y, Yang YH, Jia JP. Hypervalinemia and hyperleucine-isoleucinemia caused by mutations in the branched-chain-amino-acid aminotransferase gene. J Inherit Metab Dis. 2015;38(5):855–61. doi: 10.1007/s10545-015-9814-z.
  9. Cole JT. Metabolism of BCAAs. In: Rajendram R, Preedy VR, Patel VB, editors. Branched Chain Amino Acids in Clinical Nutrition. New York: Springer; 2015. Vol. 1. p. 13–24. doi: 10.1007/978-1-4939-1923-9_2.
  10. Chuang DT. Maple syrup urine disease: it has come a long way. J Pediatr. 1998;132(3 Pt 2):S17–23. doi: 10.1016/s0022-3476(98)70523-2.
  11. Korein J, Sansaricq C, Kalmijn M, Honig J, Lange B. Maple syrup urine disease: clinical, EEG, and plasma amino acid correlations with a theoretical mechanism of acute neurotoxicity. Int J Neurosci. 1994;79(1–2):21–45. doi: 10.3109/00207459408986065.
  12. Zhang B, Zhao Y, Harris RA, Crabb DW. Molecular defects in the E1 alpha subunit of the branched-chain alpha-ketoacid dehydrogenase complex that cause maple syrup urine disease. Mol Biol Med. 1991;8(1):39–47.
  13. Zhang B, Edenberg HJ, Crabb DW, Harris RA. Evidence for both a regulatory mutation and a structural mutation in a family with maple syrup urine disease. J Clin Invest. 1989;83(4):1425–9. doi: 10.1172/JCI114033.
  14. Nellis MM, Danner DJ. Gene preference in maple syrup urine disease. Am J Hum Genet. 2001;68(1):232–7. doi: 10.1086/316950.
  15. Zhang B, Kuntz MJ, Goodwin GW, Edenberg HJ, Crabb DW, Harris RA. cDNA cloning of the E1 alpha subunit of the branched-chain alpha-keto acid dehydrogenase and elucidation of a molecular basis for maple syrup urine disease. Ann N Y Acad Sci. 1989;573:130–6. doi: 10.1111/j.1749-6632.1989.tb14991.x.
  16. Куркина МВ, Байдакова ГВ, Захарова ЕЮ. Высокая частота гомозиготных мутаций в генах BCKDHА, BCKDHB при болезни с запахом кленового сиропа мочи у российских пациентов. Тезисы XV Российского конгресса «Инновационные технологии в педиатрии и детской хирургии». Российский вестник перинатологии и педиатрии. 2016;61(4):198.
  17. Gupta D, Bijarnia-Mahay S, Saxena R, Kohli S, Dua-Puri R, Verma J, Thomas E, Shigematsu Y, Yamaguchi S, Deb R, Verma IC. Identification of mutations, genotype-phenotype correlation and prenatal diagnosis of maple syrup urine disease in Indian patients. Eur J Med Genet. 2015;58(9):471–8. doi: 10.1016/j.ejmg.2015.08.002.
  18. Simon E, Flaschker N, Schadewaldt P, Langenbeck U, Wendel U. Variant maple syrup urine disease (MSUD) – the entire spectrum. J Inherit Metab Dis. 2006;29(6):716–24. doi: 10.1007/s10545-006-0276-1.
  19. Oyarzabal A, Martínez-Pardo M, Merinero B, Navarrete R, Desviat LR, Ugarte M, Rodríguez-Pombo P. A novel regulatory defect in the branched-chain α-keto acid dehydrogenase complex due to a mutation in the PPM1K gene causes a mild variant phenotype of maple syrup urine disease. Hum Mutat. 2013;34(2):355–62. doi: 10.1002/humu.22242.
  20. Guo Y, Liming L, Jiang L. Two novel compound heterozygous mutations in the BCKDHB gene that cause the intermittent form of maple syrup urine disease. Metab Brain Dis. 2015;30(6):1395–400. doi: 10.1007/s11011-015-9711-z.
  21. Simon E, Fingerhut R, Baumkötter J, Konstantopoulou V, Ratschmann R, Wendel U. Maple syrup urine disease: favourable effect of early diagnosis by newborn screening on the neonatal course of the disease. J Inherit Metab Dis. 2006;29(4):532–7. doi: 10.1007/s10545-006-0315-y.
  22. Classic maple syrup urine disease [Internet]. Available from: https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=268145.
  23. Hoffmann B, Helbling C, Schadewaldt P, Wendel U. Impact of longitudinal plasma leucine levels on the intellectual outcome in patients with classic MSUD. Pediatr Res. 2006;59(1):17–20. doi: 10.1203/01.pdr.0000190571.60385.34.
  24. Strauss KA, Wardley B, Robinson D, Hendrickson C, Rider NL, Puffenberger EG, Shellmer D, Moser AB, Morton DH. Classical maple syrup urine disease and brain development: principles of management and formula design. Mol Genet Metab. 2010;99(4):333–45. doi: 10.1016/j.ymgme.2009.12.007.
  25. Manara R, Del Rizzo M, Burlina AP, Bordugo A, Citton V, Rodriguez-Pombo P, Ugarte M, Burlina AB. Wernicke-like encephalopathy during classic maple syrup urine disease decompensation. J Inherit Metab Dis. 2012;35(3):413–7. doi: 10.1007/s10545-012-9456-3.
  26. Intermediate maple syrup urine disease [Internet]. Available from: https://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=20169&Disease_Disease_Search_diseaseGroup=intermedi-ate-MSUD&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Intermediate-maple-syrup-urine-disease&title=Intermediate%20maple%20syrup%20urine%20disease&search=Disease_Search_Simple.
  27. Bhattacharya K, Khalili V, Wiley V, Carpenter K, Wilcken B. Newborn screening may fail to identify intermediate forms of maple syrup urine disease. J Inherit Metab Dis. 2006;29(4):586. doi: 10.1007/s10545-006-0366-0.
  28. Intermittent maple syrup urine disease [Internet]. Available from: https://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=20170&Disease_Disease_Search_diseaseGroup=Intermittent-MSUD&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Intermittent-maple-syrup-urine-disease&title=Intermittent%20maple%20syrup%20urine%20disease&search=Disease_Search_Simple.
  29. Scriver CR, Mackenzie S, Clow CL, Delvin E. Thiamine-responsive maple-syrup-urine disease. Lancet. 1971;1(7694):310–2. doi: 10.1016/s0140-6736(71)91041-5.
  30. Shaag A, Saada A, Berger I, Mandel H, Joseph A, Feigenbaum A, Elpeleg ON. Molecular basis of lipoamide dehydrogenase deficiency in Ashkenazi Jews. Am J Med Genet. 1999;82(2):177–82. doi: 10.1002/(sici)1096-8628(19990115)82:2<177::aid-ajmg15>3.0.co;2-9.
  31. Therrell BL, Padilla CD, Loeber JG, Kneisser I, Saadallah A, Borrajo GJ, Adams J. Current status of newborn screening worldwide: 2015. Semin Perinatol. 2015;39(3):171–87. doi: 10.1053/j.semperi.2015.03.002.
  32. Oglesbee D, Sanders KA, Lacey JM, Magera MJ, Casetta B, Strauss KA, Tortorelli S, Rinaldo P, Matern D. Second-tier test for quantification of alloisoleucine and branched-chain amino acids in dried blood spots to improve newborn screening for maple syrup urine disease (MSUD). Clin Chem. 2008;54(3):542–9. doi: 10.1373/clinchem.2007.098434.
  33. Puckett RL, Lorey F, Rinaldo P, Lipson MH, Matern D, Sowa ME, Levine S, Chang R, Wang RY, Abdenur JE. Maple syrup urine disease: further evidence that newborn screening may fail to identify variant forms. Mol Genet Metab. 2010;100(2):136–42. doi: 10.1016/j.ymgme.2009.11.010.
  34. Ali EZ, Ngu LH. Fourteen new mutations of BCKDHA, BCKDHB and DBT genes associated with maple syrup urine disease (MSUD) in Malaysian population. Mol Genet Metab Rep. 2018;17:22–30. doi: 10.1016/j.ymgmr.2018.08.006.
  35. Wessel AE, Mogensen KM, Rohr F, Erick M, Neilan EG, Chopra S, Levy HL, Gray KJ, Wilkins-Haug L, Berry GT. Management of a Woman With Maple Syrup Urine Disease During Pregnancy, Delivery, and Lactation. JPEN J Parenter Enteral Nutr. 2015;39(7):875–9. doi: 10.1177/0148607114526451.
  36. Frazier DM, Allgeier C, Homer C, Marriage BJ, Ogata B, Rohr F, Splett PL, Stembridge A, Singh RH. Nutrition management guideline for maple syrup urine disease: an evidence- and consensus-based approach. Mol Genet Metab. 2014;112(3):210–7. doi: 10.1016/j.ymgme.2014.05.006.
  37. Köse M, Canda E, Kagnici M, Uçar SK, Çoker M. A Patient with MSUD: Acute management with sodium phenylacetate/sodium benzoate and sodium phenylbutyrate. Case Rep Pediatr. 2017;2017:1045031. doi: 10.1155/2017/1045031.
  38. Aygun F, Aygun D, Erbek Alp F, Zubarıoglu T, Zeybek C, Cam H. The impact of continuous renal replacement therapy for metabolic disorders in infants. Pediatr Neonatol. 2018;59(1):85–90. doi: 10.1016/j.pedneo.2017.04.004.
  39. Demirkol D, Şık G, Topal N, Çıtak A, Zeybek Ç, Tüten A, Bilge I. Continuous venovenous hemodiafiltration in the treatment of maple syrup urine disease. Blood Purif. 2016;42(1):27–32. doi: 10.1159/000443783.
  40. Puliyanda DP, Harmon WE, Peterschmitt MJ, Irons M, Somers MJ. Utility of hemodialysis in maple syrup urine disease. Pediatr Nephrol. 2002;17(4):239–42. doi: 10.1007/s00467-001-0801-2.
  41. Lynch CJ, Adams SH. Branched-chain amino acids in metabolic signalling and insulin resistance. Nat Rev Endocrinol. 2014;10(12):723–36. doi: 10.1038/nrendo.2014.171.
  42. Yasui T, Suzuki T, Hara F, Watanabe S, Uga N, Naoe A, Yoshikawa T, Ito T, Nakajima Y, Miura H, Sugioka A, Kato Y, Tokoro T, Tanahashi Y, Kasahara M, Fukuda A, Kurahashi H. Successful living donor liver transplantation for classical maple syrup urine disease. Pediatr Transplant. 2016;20(5):707–10. doi: 10.1111/petr.12738.
  43. Squires RH, Ng V, Romero R, Ekong U, Hardikar W, Emre S, Mazariegos GV; American Association for the Study of Liver Diseases; American Society of Transplantation; North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2014;59(1):112–31. doi: 10.1097/MPG.0000000000000431.
  44. Takano C, Ishige M, Ogawa E, Usui H, Kagawa R, Tajima G, Fujiki R, Fukao T, Mizuta K, Fuchigami T, Takahashi S. A case of classical maple syrup urine disease that was successfully managed by living donor liver transplantation. Pediatr Transplant. 2017;21(5). doi: 10.1111/petr.12948.
  45. Díaz VM, Camarena C, de la Vega Á, Martínez-Pardo M, Díaz C, López M, Hernández F, Andrés A, Jara P. Liver transplantation for classical maple syrup urine disease: long-term follow-up. J Pediatr Gastroenterol Nutr. 2014;59(5):636–9. doi: 10.1097/MPG.0000000000000469.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Tsareva J.A., Zryachkin N.I., Kuznetsova M.A., Bogacheva E.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies